A prominent panel of medical experts unanimously voted that there is no evidence to suggest the recently approved Alzheimer’s drug offers patients any health benefits beyond the usual care.
The meeting, which was convened to review both clinical and cost effectiveness of the new drug, is the latest blow to Biogen (BIIB) and its efforts to win acceptance amid a firestorm of controversy over study data and its dealings with the Food and Drug Administration.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
